(Q43870672)

27 November 2017

Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety (English)

1 reference

27 November 2017

0 references

1

1 reference

27 November 2017

Elena Cocuzza

2

1 reference

PubMed ID

11817515

27 November 2017

Livio Marchiaro

series ordinal

3

1 reference

PubMed ID

11817515

27 November 2017

Filippo Bogetto

series ordinal

4

1 reference

27 November 2017

1 February 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

27 November 2017

1 reference

27 November 2017

26

1 reference

27 November 2017

369-373

1 reference

27 November 2017

2

1 reference

Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

1 reference

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Management of cognition and function: new results from the clinical trials programme of Aricept(R) (donepezil HCl).

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900283-4

7 January 2021

10.1016/S0278-5846(01)00283-4

Identifiers

DOI

1 reference

27 November 2017

1 reference

PubMed ID

11817515